Results 231 to 240 of about 2,505,569 (334)

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He   +17 more
wiley   +1 more source

Multicenter study of colon capsule endoscopy in post-polypectomy surveillance. [PDF]

open access: yesEndosc Int Open
Turvill J   +9 more
europepmc   +1 more source

Etude de surveillance écologique sur le site du Blayais. Rapport général [PDF]

open access: green, 1979
J.m. Poli   +5 more
openalex  

Allelic Variation in Maize Malate Dehydrogenase 7 Shapes Promoter Methylation and Banded Leaf and Sheath Blight Resistance

open access: yesAdvanced Science, EarlyView.
In this study maize chloroplastic malate dehydrogenase7 (ZmMDH7), is identified as a Rhizoctonia solani resistance gene in maize. ZmMDH7 is regulated by transcription factor ZmWRKY44 via pathogens challenge to elevate mitochondrial ROS and SA signaling pathway.
Luyang Wei   +9 more
wiley   +1 more source

Global solidarity in genomic surveillance improves early detection of acute respiratory virus threats. [PDF]

open access: yesNat Commun
de Jong SPJ   +8 more
europepmc   +1 more source

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome

open access: yesAdvanced Science, EarlyView.
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy